Last reviewed · How we verify
Tadalafil 20 MG
At a glance
| Generic name | Tadalafil 20 MG |
|---|---|
| Also known as | Cialis, tadalafil, Adcirca, JNJ-10291697, CIALIS |
| Sponsor | University of Arizona |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension (NA)
- Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer (PHASE2)
- Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PHASE3)
- Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities (PHASE3)
- Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology (PHASE3)
- Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer (PHASE2)
- PDE5 Inhibitor for Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tadalafil 20 MG CI brief — competitive landscape report
- Tadalafil 20 MG updates RSS · CI watch RSS
- University of Arizona portfolio CI